FDA head Marty Makary is likely to be fired. While pharma’s relationship with him has been uneven, drugmakers may be even more concerned about Kennedy’s influence over his successor.

The move could curb telehealth’s copycat obesity drugs and steer patients back to branded options.

The FDA is testing real-time data feeds in studies that could speed drug approval times but also changes how drug companies submit data for review.

A recent Pfizer warning shows that regulators are leaning into policing Facebook ads as closely as TV commercials.

HRT prescriptions climb as risk fears ease and patients, doctors, and culture rethink menopause care.

The FDA’s biologics arm cited several oncology brands for misleading claims, intensifying the agency’s broader pharma marketing enforcement.

Doctronic branding itself as an “AI doctor” will trigger tougher regulatory oversight.

Marketers must build trust there with clear insurance support, patient assistance programs, and testimonials.

Novo drops court fights to secure GLP-1 distribution, which will drive other telehealth brands to weigh pharma deals against legal risk.

The FDA’s latest warning wave reinforces ongoing scrutiny of telehealth and pharma promotions.

Its pharma ad lawsuit against J&J’s promotions lands amid rising enforcement and shrinking tolerance for bold claims.

Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.

Single-study clinical trials (versus two) become the default, speeding up common drug approvals, while vaccines still face tougher scrutiny.

After an unusual review rejection, the FDA reverses course—a regulatory whiplash that could raise concerns about regulatory consistency.

The FDA’s plans for broader access of medications could boost convenience, but also raise safety risks and drug costs.

The FDA denied an application for its flu vaccine, deepening regulatory doubt and complicating forecasts for vaccine-driven revenue growth.

Rigorous data gives acetaminophen brands footing to reassure pregnant consumers.

The riff on Apple’s Mac versus PC campaign lightens the pharma tone while also leaning more into disclosures.

The change could ease stigma and fuel uptake, especially as oral weight loss drugs hit the market.

The White House issued an executive order reclassifying cannabis from a Schedule I to a Schedule III controlled substance—a lower-risk category that puts it on the same plane as some controlled prescription medications. The US legal cannabis industry is worth $35 billion and served by at least 800 FIs. Even if Congress follows through as cannabis is reclassified as a lower-risk substance, banks will likely be slow to get involved. Enhanced due diligence and reporting requirements are in force until further notice, and being in the cannabis business has a stigma among banks regardless.